Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO 2024 Breast Cancer Highlights
21 June 2024 | Virtual Meeting
Presentation summaries of breast cancer abstracts from ASCO 2024 featuring panel discussions with leading experts
Latest in ctDNA and patient stratification
RxPONDER: AMH in pts w. HR+ HER2-, node positive BC
Kevin Kalinsky Winship Cancer Institute of Emory University, Atlanta, GA, United States
Panel 1 discussion
Advances with antibody-drug conjugates
DB-06: T-DXd vs TPC for HR+ HER2-low or HER2-ultralow mBC
Giuseppe Curigliano University of Milan, Milan, Italy
SACI-IO HR+: sacituzumab govitecan +/- pembrolizumab for HR+/HER2- breast cancer
Ana Garrido-Castro Dana-Farber Cancer Institute, Boston, MA, United States
TBCRC 048: olaparib for mBC w. PALB2/BRCA1/BRCA2 mutations
Nadine Tung Beth Israel Deaconess Medical Center, Boston, MA, United States
A-BRAVE: avelumab in early TNNC after neo chemo or HR after surgery + adjuvant chemo
Pierfranco Conte University of Padova, Padova, Italy
Enfortumab vedotin in TNBC and HR+/HER2-BC cohorts of EV-202
Antonio Giordano Dana-Farber Cancer Institute, Boston, MA, United States
DESTINY-Breast07: T-DXd and T-DXd + pertuzumab for untreated HER2+ mBC
Komal Jhaveri Memorial Sloan Kettering Cancer Center, New York City, NY, United States
I-SPY2.2: Pathologic complete response after neoadjuvant datopotamab deruxtecan
Jane Meisel Winship Cancer Institute, Atlanta, GA, United States
Session 2 panel discussion
Latest in ctDNA and patient stratification
INAVO120: inavo/pbo+palbo+fulv for PIK3CAm, HR+, HER2- mBC
Dejan Juric Massachusetts General Hospital, Boston, MA, United States
SOLTI-1303: palbociclib + trastuzumab + ET in HER2+ and PAM50 luminal ABC
Eva Ciruelos 12 October University Hospital, Madrid, Spain
postMONARCH: abemaciclib + fulv vs fulv for HR+, HER2- ABC
Kevin Kalinsky Winship Cancer Institute of Emory University, Atlanta, GA, United States
Session 3 panel discussion
